BSE:BCCL News 18 January 2026

Bharat Coking Coal IPO listing Monday: Grey market signals 50%+ pop after blockbuster demand

Shares of Bharat Coking Coal Ltd will begin trading Jan. 19 after its IPO drew bids worth nearly Rs 1.17 lakh crore, subscribed 146.87 times. Grey market premiums suggest a 39–54% listing gain over the Rs 21–23 offer price. The Rs 1,071-crore offer was an offer-for-sale, with proceeds to Coal India. Analysts warn of possible profit-taking if shares jump sharply at open.

18 January 2026

BSE:BCCL·NSE:BCCL·Stock Market

Novartis stock heads into Monday with Kisqali Canada nod and $23 billion U.S. R&D build-out in focus

7 February 2026

Novartis shares closed up 0.6% in Zurich at 119.96 francs Friday, with U.S. ADRs gaining 1.5%. The company broke ground on a new San Diego research center and reported a positive draft reimbursement recommendation for Kisqali in Canada. Investors are watching for the March 6 annual meeting and March 10 ex-dividend date tied to a proposed 3.70-franc payout.

AstraZeneca stock price: What could move AZN next week as earnings loom

7 February 2026

AstraZeneca shares rose Friday, closing at $193.03 in New York, up 3.1%, and 14,104p in London, up 0.9%. The company reports full-year and Q4 2025 results Tuesday, with investors focused on 2026 guidance. The FDA this week issued a complete response letter for a subcutaneous Saphnelo filing, while granting Priority Review to Datroway for breast cancer. AstraZeneca recently shifted its primary U.S. listing to the NYSE.

Wells Fargo stock jumps to $93.97 — here’s what could move WFC next week

7 February 2026

Wells Fargo shares rose 2.63% to $93.97 Friday as U.S. stocks rebounded. The stock traded ex-dividend for a $0.45 payout due March 1. Investors await delayed U.S. jobs and inflation data next week and a scheduled CFO appearance at a bank conference.

Merck stock ends week near highs after Canada clears ENFLONSIA; insider sales surface

7 February 2026

Merck shares closed up 1.8% at $121.93 Friday after Health Canada approved its ENFLONSIA RSV antibody for infants. Guggenheim raised its price target to $140. Insider filings showed three executives sold shares this week. Merck’s stock ended just below its 52-week high, with about 13 million shares traded.

BSE:BCCL News 18 January 2026

Bharat Coking Coal IPO listing Monday: Grey market signals 50%+ pop after blockbuster demand

Stock Market Today

Novartis stock heads into Monday with Kisqali Canada nod and $23 billion U.S. R&D build-out in focus

AstraZeneca stock price: What could move AZN next week as earnings loom

Wells Fargo stock jumps to $93.97 — here’s what could move WFC next week

Merck stock ends week near highs after Canada clears ENFLONSIA; insider sales surface